As Cisco Sys (CSCO) Share Value Declined, Town & Country Bank & Trust Company Dba First …

Horizon Investments Llc bought 36,965 shares as the company’s stock rose 2.15% . … 22,426 were accumulated by Quantum Capital Management.

Cisco Systems, Inc. (NASDAQ:CSCO) Logo

Town & Country Bank & Trust Company Dba First Bankers Trust Company increased its stake in Cisco Sys Inc (CSCO) by 9.15% based on its latest 2019Q2 regulatory filing with the SEC. Town & Country Bank & Trust Company Dba First Bankers Trust Company bought 6,239 shares as the company’s stock declined 0.32% . The institutional investor held 74,409 shares of the technology company at the end of 2019Q2, valued at $4.07 million, up from 68,170 at the end of the previous reported quarter. Town & Country Bank & Trust Company Dba First Bankers Trust Company who had been investing in Cisco Sys Inc for a number of months, seems to be bullish on the $212.39 billion market cap company. The stock increased 0.20% or $0.1 during the last trading session, reaching $50.03. About 11.62M shares traded. Cisco Systems, Inc. (NASDAQ:CSCO) has risen 31.37% since September 14, 2018 and is uptrending. It has outperformed by 31.37% the S&P500. Some Historical CSCO News: 19/03/2018 – CED Magazine: Verizon Tests Cisco Open-Source Networking Technology; 03/04/2018 – $FNJN $CSCO Finjan prevails against Cisco Systems as both ‘494 and ‘844 IPR patent challenge trials are denied; 12/04/2018 – CISCO NAMES MARK GARRETT TO BOARD; 01/05/2018 – Techmeme: Private equity firm Permira is buying Cisco’s video software business, known as the NDS Group, sources say for ~$1B;; 10/04/2018 – Cisco Tetration Workload Protection Extended with New Options: SaaS and Virtual Appliance; 15/05/2018 – Leading Marketing Innovators from Marketo and Cisco to Keynote This Year’s BRAND INNOVATION QUEST® in Chicago; 23/05/2018 – Cyber firms warn on suspected Russian plan to attack Ukraine; 15/05/2018 – ♫ Reuters Insider – U.S. Day Ahead: Macy’s goes for two quarters of sales growth in a row; 28/03/2018 – ARISTA NETWORKS INC – BOTH PATENT TRIAL & APPEAL BOARD AND FEDERAL CIRCUIT DETERMINED ‘668 PATENT TO BE UNPATENTABLE ON ALL RELEVANT CLAIMS; 16/05/2018 – Cisco Systems Sees 4Q Non-GAAP Gross Margin Rate 63% – 64%

Horizon Investments Llc increased its stake in Glaxosmithkline Plc Sponsored (GSK) by 57.5% based on its latest 2019Q2 regulatory filing with the SEC. Horizon Investments Llc bought 36,965 shares as the company’s stock rose 2.15% . The institutional investor held 101,248 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $4.05 million, up from 64,283 at the end of the previous reported quarter. Horizon Investments Llc who had been investing in Glaxosmithkline Plc Sponsored for a number of months, seems to be bullish on the $101.09B market cap company. The stock decreased 0.34% or $0.14 during the last trading session, reaching $40.89. About 1.89M shares traded. GlaxoSmithKline plc (NYSE:GSK) has risen 0.49% since September 14, 2018 and is uptrending. It has outperformed by 0.49% the S&P500. Some Historical GSK News: 27/03/2018 – GLAXOSMITHKLINE CONSUMER HEALTHCARE – STRATEGIC REVIEW OF; 23/03/2018 – GSK pulls out of $20 bln race for Pfizer consumer assets; 23/03/2018 – SHINGRIX APPROVED IN EUROPE AND JAPAN; 27/03/2018 – Market Talk Roundup: GSK Buys Novartis’s Stake in Joint Venture; 30/05/2018 – Cloud Pharmaceuticals forms Drug Design Collaboration with GSK; 27/03/2018 – NOVARTIS SAYS SALE OF JV IN A NON-CORE SEGMENT IN BEST LONG-TERM INTERESTS OF NOVARTISSHAREHOLDERS; 21/05/2018 – ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV; 24/04/2018 – GSK,INNOVIVA: FDA OKS EXPANDED INDICATION FOR TRELEGY ELLIPTA; 09/05/2018 – GlaxoSmithKline Chief Financial Officer Simon Dingemans to Retire; 27/03/2018 – Novartis sells joint venture stake to GSK

Since June 7, 2019, it had 1 buying transaction, and 0 insider sales for $557,404 activity.

Investors sentiment decreased to 0.76 in 2019 Q2. Its down 0.07, from 0.83 in 2019Q1. It fall, as 39 investors sold CSCO shares while 775 reduced holdings. 146 funds opened positions while 472 raised stakes. 2.94 billion shares or 2.81% less from 3.03 billion shares in 2019Q1 were reported. 22,426 were accumulated by Quantum Capital Management. Birinyi Assoc Incorporated reported 6,323 shares. 16,064 are owned by Renaissance Group Limited Liability Co. Wagner Bowman Corporation has 61,580 shares. Manufacturers Life Ins The has invested 0.47% in Cisco Systems, Inc. (NASDAQ:CSCO). Intrepid Cap holds 64,914 shares or 1.61% of its portfolio. Ntv Asset Management Ltd Liability Corp has 72,495 shares for 1.14% of their portfolio. Eagle Glob Advsrs Ltd Liability holds 0.73% of its portfolio in Cisco Systems, Inc. (NASDAQ:CSCO) for 332,802 shares. Company Natl Bank reported 1.65 million shares. Amer National Registered Advisor stated it has 1.03% of its portfolio in Cisco Systems, Inc. (NASDAQ:CSCO). Meag Munich Ergo Kapitalanlagegesellschaft Mbh has 0.79% invested in Cisco Systems, Inc. (NASDAQ:CSCO). Naples Global Advsrs Ltd Liability Corp invested in 0.72% or 53,699 shares. Regent Inv Mgmt Limited Liability Co reported 1.73% stake. Dubuque National Bank Comm owns 302,301 shares. Cutter And Brokerage Incorporated owns 15,593 shares.

More notable recent Cisco Systems, Inc. (NASDAQ:CSCO) news were published by: Nasdaq.com which released: “Technology Sector Update for 08/30/2019: SEAC, MSFT, AAPL, IBM, CSCO, GOOGL – Nasdaq” on August 30, 2019, also Nasdaq.com with their article: “Should You Buy Cisco Systems (CSCO) Ahead of Earnings? – Nasdaq” published on August 12, 2019, Investorideas.com published: “Newswire – The AI Eye: Cisco (Nasdaq: $CSCO) to Acquire CloudCherry, NVIDIA (Nasdaq: $NVDA) and VMware (NYSE: $VMW) to Deliver Accelerated GPU Services on Cloud for AWS (Nasdaq: $AMZN) – InvestorIdeas.com” on August 26, 2019. More interesting news about Cisco Systems, Inc. (NASDAQ:CSCO) were released by: Nasdaq.com and their article: “Trade War Pain Comes to Cisco Systems – Nasdaq” published on August 15, 2019 as well as Marketwatch.com‘s news article titled: “Cisco’s stock had its worst single-day drop in almost six years – MarketWatch” with publication date: August 17, 2019.

Town & Country Bank & Trust Company Dba First Bankers Trust Company, which manages about $216.43 million US Long portfolio, decreased its stake in Bristol Myers Squibb Co (NYSE:BMY) by 11,156 shares to 46,528 shares, valued at $2.11M in 2019Q2, according to the filing. It also reduced its holding in Enterprise Prods Partners L (NYSE:EPD) by 27,774 shares in the quarter, leaving it with 22,353 shares, and cut its stake in Lilly Eli & Co (NYSE:LLY).

Horizon Investments Llc, which manages about $1.50 billion and $3.59B US Long portfolio, decreased its stake in Waste Mgmt Inc Del Com (NYSE:WM) by 24,444 shares to 9,321 shares, valued at $1.08M in 2019Q2, according to the filing. It also reduced its holding in Wec Energy Group Inc Com by 9,833 shares in the quarter, leaving it with 7,743 shares, and cut its stake in Duke Energy Corp New Com New (NYSE:DUK).

More notable recent GlaxoSmithKline plc (NYSE:GSK) news were published by: Finance.Yahoo.com which released: “Here’s What Hedge Funds Think About GlaxoSmithKline plc (GSK) – Yahoo Finance” on June 14, 2019, also Bizjournals.com with their article: “GSK’s new pharma president carries Merck, Pfizer experience – Triangle Business Journal” published on August 13, 2019, Fool.com published: “Better Buy: Eli Lilly vs. GlaxoSmithKline – The Motley Fool” on August 18, 2019. More interesting news about GlaxoSmithKline plc (NYSE:GSK) were released by: Seekingalpha.com and their article: “Glaxo launches late-stage development of RA med otilimab – Seeking Alpha” published on July 03, 2019 as well as Seekingalpha.com‘s news article titled: “Glaxo sells parcel in India for $125M – Seeking Alpha” with publication date: August 30, 2019.

Cisco Systems, Inc. (NASDAQ:CSCO) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

GSK takes over full ownership of Sitari Pharmaceuticals

Avalon Ventures declared that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari prescription drugs by GSK.

Avalon Ventures declared that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari prescription drugs by GSK. Sitari has been developing a completely unique treatment for the disorder and was the primary company shaped underneath the GSK-Avalon venture collaboration in 2013. Sitari was incubated at COI prescription drugs, the Community of Innovation established by Avalon Ventures. Sitari’s diagnosis program has the potential to become medication to assist several patients with the disorder, a pacesetter in developing innovative medicines, are advancing the program Sitari’s TG2 inhibitors have the potential to suppress the response that ends up in internal organ inflammation and cell pathologic process in celiac patients. Over the last six years, GSK and Avalon have pioneered a singular biotech funding model designed to spot novel targets from top-tier tutorial labs and translate up-to-date discoveries into promising clinical candidates. Bringing the Sitari TG2 program into GSK is powerfully aligned with our analysis specialize in genetically associated targets and immune-driven illness. this commonplace of taking care of disorder is strict adherence to a diet, however a major range of patients still expertise duct symptoms and illness progression. TG2 inhibition may represent a replacement hope for disorder patients. The first-of-its-kind collaboration between Avalon Ventures and GSK combined Avalon’s productive approach of finance in early-stage natural science innovation with GSK’s experience and resources in drug discovery and development. The eight firms shaped underneath the collaboration were incubated at COI prescription drugs, Community of Innovation, wherever they received government leadership and operational management. underneath the terms of the agreement, GSK noninheritable Sitari and every one of its belongings. money terms weren’t disclosed.

Related Posts:

  • No Related Posts

GlaxoSmithKline’s Acquisition Of Sitari Pharmaceuticals: Details About The Deal

Avalon Ventures announced it entered a deal with GlaxoSmithKline for the acquisition of Sitari Pharmaceuticals by GSK. These are the details behind …
  • Avalon Ventures announced it entered a deal with GlaxoSmithKline for the acquisition of Sitari Pharmaceuticals by GSK. These are the details behind the deal.

Avalon Ventures recently announced that it entered a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK. Sitari is known for developing a novel treatment for celiac disease and it was the first company formed under the GSK-Avalon venture collaboration in 2013. Sitari was incubated at COI Pharmaceuticals — which is the Community of Innovation established by Avalon Ventures. The terms of the deal were undisclosed

“Our collaboration with GSK has been overwhelmingly positive as we were able to rapidly launch a series of new companies based on promising scientific research, and we successfully advanced five programs into preclinical studies for a variety of unmet medical needs,” said Jay Lichter, Ph.D. — who is the CEO of Sitari, president and CEO of COI, and managing director of Avalon Ventures. “Sitari’s preclinical program has the potential to become a medicine to help millions of patients with celiac disease, and we are excited that GSK, a leader in developing innovative medicines, will be advancing the program.”

ADVERTISEMENT

Genetic predisposition is known for playing a key role in celiac disease — which is an autoimmune digestive disorder caused by intolerance to gluten (a protein found in wheat, rye, and barley that damages the small intestine and interferes with absorption of nutrients from food).

The enzymatic activity of transglutaminase 2 (TG2) is responsible for triggering the inflammatory cascade in response to gluten exposure in patients with celiac disease. And Sitari’s TG2 inhibitors have the potential to suppress the autoimmune response that results in intestinal inflammation and cell pathogenesis in celiac patients.

ADVERTISEMENT

“Over the last six years, GSK and Avalon have pioneered a unique biotech funding model designed to identify novel targets from top-tier academic labs and translate cutting-edge discoveries into promising clinical candidates,” said John Lepore, the SVP of Research at GSK. “Bringing the Sitari TG2 program into GSK is strongly aligned with our research focus on genetically-associated targets and immune-driven disease. The current standard of care for celiac disease is strict adherence to a gluten-free diet, but a significant number of patients still experience gastrointestinal symptoms and disease progression. TG2 inhibition could represent a new hope for celiac disease patients.”

This is a first-of-its-kind collaboration between Avalon Ventures and GSK combined Avalon’s successful approach of investing in early-stage life science innovation with GSK’s expertise and resources in drug discovery and development. And the 8 companies that were formed under the collaboration were incubated at COI Pharmaceuticals where they received access to executive leadership and operational management.

As part of the agreement, GSK had acquired Sitari and all of its intellectual property.

Related Posts:

  • No Related Posts

EuroBiotech Report—Sanofi pays to scrap deal, BioNTech IPO, GSK takeover, Roche and 4BIO

GlaxoSmithKline struck a deal to buy a celiac disease startup it founded with Avalon Ventures. Roche posted phase 3 data on its candidate for the …

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with Sanofi, which finally extracted itself from its deal with Lexicon Pharmaceuticals—for a price. Sanofi is set to pay $260 million to terminate a contract covering dual SGLT1-SGLT2 inhibitor Zynquista. Elsewhere, BioNTech filed to raise $100 million in an IPO shortly after an investor went back on a commitment to give it $88 million. GlaxoSmithKline struck a deal to buy a celiac disease startup it founded with Avalon Ventures. Roche posted phase 3 data on its candidate for the competitive neuromyelitis optica spectrum disorder market. 4BIO Capital raised $50 million to back advanced therapy startups with ambitions to break out of super-rare diseases. And more. — Nick Taylor

1. Sanofi to pay $260M to exit Lexicon diabetes pact

Sanofi is set to pay Lexicon Pharmaceuticals $260 million (€236 million) to get out of a diabetes pact. The dissolution of the alliance follows the generation of mixed clinical data on Zynquista in Type 1 diabetics that failed to persuade the FDA to approve the dual SGLT1-SGLT2 inhibitor.

2. BioNTech files for IPO after investor reneges on $88M promise

BioNTech has filed to raise $100 million (€90 million) in a Nasdaq IPO. The proposal, which comes shortly after a $325 million series B, would set BioNTech up to run clinical trials of three mRNA assets while funding its share of collaborations with Genentech, Sanofi and Genmab.

3. GSK buys celiac startup Sitari 6 years after founding it with Avalon

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

GlaxoSmithKline has struck a deal to buy Sitari Pharmaceuticals, the first company created through its collaboration with Avalon Ventures.

4. Roche’s satralizumab cuts relapse risk in rare disease phase 3

Roche has presented phase 3 data on its neuromyelitis optica spectrum disorder treatment satralizumab. The trial linked the anti-IL-6 antibody to a 55% reduction in the risk of relapse, showing the drug works but leaving scope to question how it will fare against rival drugs.

5. 4BIO raises VC fund to take cell and gene therapies mainstream

4BIO Capital has raised $50 million (€45 million) to invest in advanced therapy startups. The specialist venture capital player plans to pump the money, plus another $100 million it hopes to add by the final close, into companies that are working to extend use of advanced therapies to major diseases such as diabetes and rheumatoid arthritis.

And more articles of note>>

Related Posts:

  • No Related Posts

Avalon Ventures and COI Pharmaceuticals Announce Acquisition of Sitari Pharmaceuticals by GSK

GSK to obtain transglutaminase 2 small molecule program for celiac disease. SAN DIEGO, CA, USA I September 12, 2019 I Avalon Ventures today …

Avalon Ventures and COI Pharmaceuticals Announce Acquisition of Sitari Pharmaceuticals by GSK

Details
Category: More News
Published on Thursday, 12 September 2019 14:06
Hits: 360

GSK to obtain transglutaminase 2 small molecule program for celiac disease

SAN DIEGO, CA, USA I September 12, 2019 I Avalon Ventures today announced that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK. Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon venture collaboration in 2013. Sitari was incubated at COI Pharmaceuticals, the Community of Innovation established by Avalon Ventures.

“Our collaboration with GSK has been overwhelmingly positive as we were able to rapidly launch a series of new companies based on promising scientific research, and we successfully advanced five programs into preclinical studies for a variety of unmet medical needs,” said Jay Lichter, Ph.D., CEO of Sitari, president and CEO of COI, and managing director of Avalon Ventures. “Sitari’s preclinical program has the potential to become a medicine to help millions of patients with celiac disease, and we are excited that GSK, a leader in developing innovative medicines, will be advancing the program.”

Genetic predisposition plays a key role in celiac disease, which is an autoimmune digestive disorder caused by intolerance to gluten, a protein found in wheat, rye, and barley, that damages the small intestine and interferes with absorption of nutrients from food. The enzymatic activity of transglutaminase 2(TG2) is responsible for triggering the inflammatory cascade in response to gluten exposure in patients with celiac disease. Sitari’s TG2 inhibitors have the potential to suppress the autoimmune response that results in intestinal inflammation and cell pathogenesis in celiac patients.

“Over the last six years, GSK and Avalon have pioneered a unique biotech funding model designed to identify novel targets from top-tier academic labs and translate cutting-edge discoveries into promising clinical candidates,” said John Lepore, SVP, Research, GSK. “Bringing the Sitari TG2 program into GSK is strongly aligned with our research focus on genetically-associated targets and immune-driven disease. The current standard of care for celiac disease is strict adherence to a gluten-free diet, but a significant number of patients still experience gastrointestinal symptoms and disease progression. TG2 inhibition could represent a new hope for celiac disease patients.”

The first-of-its-kind collaboration between Avalon Ventures and GSK combined Avalon’s successful approach of investing in early-stage life science innovation with GSK’s expertise and resources in drug discovery and development. The eight companies formed under the collaboration were incubated at COI Pharmaceuticals, Community of Innovation, where they received executive leadership and operational management. Under the terms of the agreement, GSK acquired Sitari and all of its intellectual property. Financial terms were not disclosed.

About COI Pharmaceuticals

COI Pharmaceuticals is a life science incubator entity that provides inventors with an environment where entrepreneurial and scientific risks are encouraged and rewarded. This Community of Innovation (COI) was established in 2013 to support a portfolio of companies that included those funded through a collaboration between Avalon Ventures and GSK. COI provides the intellectual capital to launch companies, a fully-equipped R&D infrastructure and industry mentors prepared to leverage their expertise to help entrepreneurial scientists succeed. COI is located in La Jolla, California. For more information, please visit: www.coipharma.com.

About Avalon Ventures

Avalon Ventures is a venture capital firm that has founded and/or funded more than 127 information technology and life sciences companies. The firm is passionate about backing talented entrepreneurs seeking to build market-leading companies. Throughout the firm’s 32-year tenure, Avalon’s long-standing and successful focus has been on seed and early-stage companies. All Avalon partners are seasoned entrepreneurs with experience in company formation, operations, and value creation in the life science and tech sectors. Avalon’s current fund, launched in 2015, continues the firm’s tradition of pursuing disruptive ideas in ever changing markets. For more information, please visit: www.avalon-ventures.com.

SOURCE: Avalon Ventures

Related Posts:

  • No Related Posts